The biology predicted the outcome before the studies confirmed it
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, et al
It is anticipated that the patient will require a ventriculoperitoneal shunt permanently
Silencing HSD17B13 has been reported to attenuate fibrosis, potentially via effects on pyrimidine catabolism, although complete deficiency does not uniformly protect against MASH in mice [58]
Blood pressure and blood sugar markers start normalizing
Injection site reactions mild redness or small bump is normal